RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $420
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (VRTX) and increased the price target from $397 to $420.
February 06, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals and raised the price target from $397 to $420.
The increase in price target by RBC Capital suggests a positive outlook on Vertex Pharmaceuticals' stock performance in the short term. Given the specificity of the adjustment and the credibility of the analyst, this news is likely to be viewed positively by investors, potentially leading to an uptick in VRTX's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100